283 related articles for article (PubMed ID: 28293857)
1. Effect of cilostazol in treating diabetes-associated microvascular complications.
Asal NJ; Wojciak KA
Endocrine; 2017 May; 56(2):240-244. PubMed ID: 28293857
[TBL] [Abstract][Full Text] [Related]
2. [Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol].
Rosa MP; Baroni GV; Portal VL
Arq Bras Endocrinol Metabol; 2007 Dec; 51(9):1528-32. PubMed ID: 18209897
[TBL] [Abstract][Full Text] [Related]
3. Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of diabetes mellitus type 2 (ASCEND).
Rosales RL; Santos MM; Mercado-Asis LB
Angiology; 2011 Nov; 62(8):625-35. PubMed ID: 21733952
[TBL] [Abstract][Full Text] [Related]
4. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats.
Wang F; Li M; Cheng L; Zhang T; Hu J; Cao M; Zhao J; Guo R; Gao L; Zhang X
Life Sci; 2008 Dec; 83(25-26):828-35. PubMed ID: 18983856
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
[TBL] [Abstract][Full Text] [Related]
6. AMPK in microvascular complications of diabetes and the beneficial effects of AMPK activators from plants.
Shrikanth CB; Nandini CD
Phytomedicine; 2020 Jul; 73():152808. PubMed ID: 30935723
[TBL] [Abstract][Full Text] [Related]
7. Effect of cilostazol on experimental diabetic neuropathy in the rat.
Kihara M; Schmelzer JD; Low PA
Diabetologia; 1995 Aug; 38(8):914-8. PubMed ID: 7589876
[TBL] [Abstract][Full Text] [Related]
8. Effects of sarpogrelate on microvascular complications with type 2 diabetes.
Yoo H; Park I; Kim DJ; Lee S
Int J Clin Pharm; 2019 Apr; 41(2):563-573. PubMed ID: 30864083
[TBL] [Abstract][Full Text] [Related]
9. Cilostazol in diabetic neuropathy: premature farewell or new beginning?
Papanas N; Maltezos E
Angiology; 2011 Nov; 62(8):605-8. PubMed ID: 21511679
[TBL] [Abstract][Full Text] [Related]
10. The role of protein kinase C activation and the vascular complications of diabetes.
Das Evcimen N; King GL
Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.
Aoki M; Morishita R; Hayashi S; Jo N; Matsumoto K; Nakamura T; Kaneda Y; Ogihara T
Diabetologia; 2001 Aug; 44(8):1034-42. PubMed ID: 11484082
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol: treatment of intermittent claudication.
Reilly MP; Mohler ER
Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
[TBL] [Abstract][Full Text] [Related]
13. The US experience with cilostazol in treating intermittent claudication.
Hiatt WR
Atheroscler Suppl; 2005 Dec; 6(4):21-31. PubMed ID: 16275166
[TBL] [Abstract][Full Text] [Related]
14. Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB.
Lee WC; Chen HC; Wang CY; Lin PY; Ou TT; Chen CC; Wen MC; Wang J; Lee HJ
Biosci Biotechnol Biochem; 2010; 74(7):1355-61. PubMed ID: 20622454
[TBL] [Abstract][Full Text] [Related]
15. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
[TBL] [Abstract][Full Text] [Related]
16. Administration of Traditional Chinese Blood Circulation Activating Drugs for Microvascular Complications in Patients with Type 2 Diabetes Mellitus.
He L; Wang H; Gu C; He X; Zhao L; Tong X
J Diabetes Res; 2016; 2016():1081657. PubMed ID: 27830156
[TBL] [Abstract][Full Text] [Related]
17. Treating peripheral arterial disease in patients with diabetes.
Hittel N; Donnelly R
Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S26-31. PubMed ID: 12180355
[TBL] [Abstract][Full Text] [Related]
18. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Uchikawa T; Murakami T; Furukawa H
Arzneimittelforschung; 1992 Mar; 42(3):322-4. PubMed ID: 1497693
[TBL] [Abstract][Full Text] [Related]
19. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?
Leiter LA
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl 2():S3-14. PubMed ID: 15953505
[TBL] [Abstract][Full Text] [Related]
20. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy.
Omoto S; Nomura S; Shouzu A; Hayakawa T; Shimizu H; Miyake Y; Yonemoto T; Nishikawa M; Fukuhara S; Inada M
Nephron; 1999; 81(3):271-7. PubMed ID: 10050080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
